Recently, it was shown to suppress the resistance of prostate cancer cells to enzalutamide [185], and its analogs SG-1709 (Figure 3b) and SG-1721 (Figure 3c) exhibited even greater effectiveness in blocking STAT3 signaling and inducing apoptosis. Here, STAT3 is linked to prostate carcinoma.